Faster global financial news!
Biotechnology
-
The U.S. Treasury Department last week released a draft of outbound investment restrictions targeting Chinese biotechnology companies
The U.S. Treasury Department last week released a draft of outbound investment restrictions targeting Chinese biotechnology companies, aiming to prevent U.S. investment from flowing into these firms t
-
Moderna CEO Says Company Seeks China Partnerships Despite Geopolitical Tensions
Moderna CEO Stephane Bancel told Nikkei Asia that the U.S. biotechnology company, known for its COVID-19 vaccine, is "in multiple discussions in Greater China" to seek potential partnerships aimed at
-
NVIDIA-backed AI biotech company Iambic Therapeutics saw its stock price rise 16% on its first day of trading.
Shares of Iambic Therapeutics Inc., an AI-powered biotechnology company backed by NVIDIA, surged 16% on its first day of trading after raising $150 million in its U.S. initial public offering (IPO). A
-
Forbion Completes $2.6 Billion Fundraise, Boosting European Biotech Industry
The Dutch company's fundraising boosts Europe's biotech industry, despite prior warnings from European drugmakers and investors that the region was losing its edge.
-
US President issues executive order to combat disease-carrying pests, targeting 90% reduction in invasive mosquitoes and 50% in ticks by 2028
The order mandates the Secretaries of the Interior, Agriculture, and Health and Human Services, along with the Administrators of the Environmental Protection Agency and General Services, to develop an
-
AI biotech Enveda secures $311M Series E funding at $2B valuation
The funding round was led by Catalio Capital Management, with participation from Iconiq and others, doubling Enveda's valuation from 12 months ago. The startup, founded in 2019, uses AI to discover ne
-
Analysts: Rising US scrutiny on clinical trials could threaten China’s biotech advantage
Analysts warn that China's edge in fast, cost-effective early clinical trials, which has propelled its emergence as a global biopharmaceutical powerhouse, is at risk. US lawmakers and Food and Drug Ad
-
Bloomberg: Big Pharma Bets on China's New Drugs, Potentially Impacting US Biotech Dominance
Bloomberg reports that major pharmaceutical companies are looking to China for their next generation of blockbuster drugs. This shift could have profound implications for patients and the future domin
-
INNBC Coin: Status and Risk Analysis of a Decentralized Scientific Research Token
Innovative Bioresearch Coin (INNBC) is a token launched by Innovative Bioresearch Ltd., aiming to leverage blockchain technology to advance scientific research in areas such as AIDS and cancer. The project claims to be the first crypto project with scientific publications on PubMed, and the token is used to access its medical products and services. However, as of August 2026, INNBC's market performance is extremely poor, with 24-hour trading volume close to zero, and significant inconsistencies in its market capitalization and supply data. Investors considering its long-term potential should be highly cautious of the high risks associated with its extremely low liquidity and data uncertainties.
-
China Life's H1 revenue surged 81.5% to 434.3 billion yuan ($64.6 billion), net profit rose over 228% to 134.5 billion yuan, as it plans to boost investment in AI, chips, and biotech
China Life Insurance, the country’s largest life insurer, released its interim results on Thursday, showing record highs in both revenue and net profit. The company stated it will scale up investments
-
White House to Announce New Drug Pricing Deals with Biotechs
White House to Announce New Drug Pricing Deals with Biotechs
-
ARNA Panacea Project Analysis: How Does Blockchain Empower Biotechnology and Clinical Trials?
ARNA Panacea is a biotechnology decentralized solution based on the Ethereum blockchain, launched in 2017. The project aims to leverage blockchain technology to process clinical trial data, providing a transparent and immutable platform for market participants such as researchers, patients, regulatory bodies, and pharmaceutical companies, and supporting the direct sale of biotechnology products. Its core token is ARNA, an ERC20 standard token. The platform also enhances data immutability by submitting hashes to the Bitcoin blockchain. ARNA Genomics, as a related entity, has received funding and awards for its breast cancer detection system, but the public supply and trading data for the token are unknown.
-
TG Therapeutics (TGTX) stock outperforms 95% of stocks, selected for IBD 50 Growth Stocks To Watch
The biotechnology company, which focuses on multiple sclerosis treatments, was chosen as Monday's IBD 50 Growth Stocks To Watch selection. Wall Street anticipates explosive earnings growth for TG Ther
-
NVIDIA invested $10.4 million in biotech company Generate Biomedicines through its venture capital arm NVentures, making it one of NVIDIA's top five holdings.
NVIDIA invested $10.4 million in biotech company Generate Biomedicines through its venture capital arm NVentures, making it one of NVIDIA's top five holdings.
-
The family office run by billionaire Stanley Druckenmiller purchased 316,000 shares of Revolution Medicines (RVMD) in the first quarter; the company’s stock price has risen more than 134% so far this year.
Duquesne Family Office, run by billionaire investor Stanley Druckenmiller, purchased 316,000 shares of biotechnology company Revolution Medicines (RVMD) in the first quarter.The company’s stock price
-
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
An analysis article on Yahoo Finance compared two healthcare-themed ETFs: the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Biotechnology & Genome ETF (PBE). The analysis noted
-
The U.S. Treasury Department last week released a draft of outbound investment restrictions targeting Chinese biotechnology companies
The U.S. Treasury Department last week released a draft of outbound investment restrictions targeting Chinese biotechnology companies, aiming to prevent U.S. investment from flowing into these firms t
-
Moderna CEO Says Company Seeks China Partnerships Despite Geopolitical Tensions
Moderna CEO Stephane Bancel told Nikkei Asia that the U.S. biotechnology company, known for its COVID-19 vaccine, is "in multiple discussions in Greater China" to seek potential partnerships aimed at
-
NVIDIA-backed AI biotech company Iambic Therapeutics saw its stock price rise 16% on its first day of trading.
Shares of Iambic Therapeutics Inc., an AI-powered biotechnology company backed by NVIDIA, surged 16% on its first day of trading after raising $150 million in its U.S. initial public offering (IPO). A
-
Forbion Completes $2.6 Billion Fundraise, Boosting European Biotech Industry
The Dutch company's fundraising boosts Europe's biotech industry, despite prior warnings from European drugmakers and investors that the region was losing its edge.
-
US President issues executive order to combat disease-carrying pests, targeting 90% reduction in invasive mosquitoes and 50% in ticks by 2028
The order mandates the Secretaries of the Interior, Agriculture, and Health and Human Services, along with the Administrators of the Environmental Protection Agency and General Services, to develop an
-
AI biotech Enveda secures $311M Series E funding at $2B valuation
The funding round was led by Catalio Capital Management, with participation from Iconiq and others, doubling Enveda's valuation from 12 months ago. The startup, founded in 2019, uses AI to discover ne
-
Analysts: Rising US scrutiny on clinical trials could threaten China’s biotech advantage
Analysts warn that China's edge in fast, cost-effective early clinical trials, which has propelled its emergence as a global biopharmaceutical powerhouse, is at risk. US lawmakers and Food and Drug Ad
-
Bloomberg: Big Pharma Bets on China's New Drugs, Potentially Impacting US Biotech Dominance
Bloomberg reports that major pharmaceutical companies are looking to China for their next generation of blockbuster drugs. This shift could have profound implications for patients and the future domin
-
China Life's H1 revenue surged 81.5% to 434.3 billion yuan ($64.6 billion), net profit rose over 228% to 134.5 billion yuan, as it plans to boost investment in AI, chips, and biotech
China Life Insurance, the country’s largest life insurer, released its interim results on Thursday, showing record highs in both revenue and net profit. The company stated it will scale up investments
-
White House to Announce New Drug Pricing Deals with Biotechs
White House to Announce New Drug Pricing Deals with Biotechs
-
TG Therapeutics (TGTX) stock outperforms 95% of stocks, selected for IBD 50 Growth Stocks To Watch
The biotechnology company, which focuses on multiple sclerosis treatments, was chosen as Monday's IBD 50 Growth Stocks To Watch selection. Wall Street anticipates explosive earnings growth for TG Ther
-
NVIDIA invested $10.4 million in biotech company Generate Biomedicines through its venture capital arm NVentures, making it one of NVIDIA's top five holdings.
NVIDIA invested $10.4 million in biotech company Generate Biomedicines through its venture capital arm NVentures, making it one of NVIDIA's top five holdings.
-
The family office run by billionaire Stanley Druckenmiller purchased 316,000 shares of Revolution Medicines (RVMD) in the first quarter; the company’s stock price has risen more than 134% so far this year.
Duquesne Family Office, run by billionaire investor Stanley Druckenmiller, purchased 316,000 shares of biotechnology company Revolution Medicines (RVMD) in the first quarter.The company’s stock price
-
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
An analysis article on Yahoo Finance compared two healthcare-themed ETFs: the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Biotechnology & Genome ETF (PBE). The analysis noted
-
INNBC Coin: Status and Risk Analysis of a Decentralized Scientific Research Token
Innovative Bioresearch Coin (INNBC) is a token launched by Innovative Bioresearch Ltd., aiming to leverage blockchain technology to advance scientific research in areas such as AIDS and cancer. The project claims to be the first crypto project with scientific publications on PubMed, and the token is used to access its medical products and services. However, as of August 2026, INNBC's market performance is extremely poor, with 24-hour trading volume close to zero, and significant inconsistencies in its market capitalization and supply data. Investors considering its long-term potential should be highly cautious of the high risks associated with its extremely low liquidity and data uncertainties.
-
ARNA Panacea Project Analysis: How Does Blockchain Empower Biotechnology and Clinical Trials?
ARNA Panacea is a biotechnology decentralized solution based on the Ethereum blockchain, launched in 2017. The project aims to leverage blockchain technology to process clinical trial data, providing a transparent and immutable platform for market participants such as researchers, patients, regulatory bodies, and pharmaceutical companies, and supporting the direct sale of biotechnology products. Its core token is ARNA, an ERC20 standard token. The platform also enhances data immutability by submitting hashes to the Bitcoin blockchain. ARNA Genomics, as a related entity, has received funding and awards for its breast cancer detection system, but the public supply and trading data for the token are unknown.
Biotechnology
24H Trending
-
1
The Nikkei 225 index is down 2.72% from its previous close, currently at 62,903.43.
-
2
South Korea's KOSPI index is down 4.77% from its previous close, currently at 5,654.61.
-
3
The Shanghai Composite Index fell 1.16% from its previous close to 3,609.01.
-
4
Samsung Electronics is down 5.82% from its previous close, now trading at ₩218,500.
-
5
Taiwan's TAIEX fell 2.68% from its previous close, currently at 45,125.33.
-
6
SK Hynix is down 8.06% from its previous close, now trading at ₩1,403,000.
-
7
Analysts: Middle East Conflict Supports Energy Storage Demand, CATL, BYD, and Gotion High-tech Expected to Benefit
-
8
Cryptocurrency Buyback and Burn Mechanism: A Multi-faceted Benefit Analysis
-
9
PUNDIX Coin Value Analysis: Current Status and Investment Considerations for Pundi X Token
-
10
Coin98 (C98) Token: Total Supply, Circulating Status, and Investment Outlook Analysis
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
